REQUEST: Compliance, risk, and IT security reader perspective

Begin 10-minute survey

(We're sending the first 50 qualified respondents a $5 Starbucks gift card)

Are you involved in your organization's compliance, risk, privacy or IT security strategy? Do you work at a biotech, pharmaceutical, clinical research organization, university or medical device manufacturer? If so, FiercePharma urgently seeks your expert opinion.

FiercePharma is conducting research on behalf of a trusted partner about privacy and security implications brought forth by the explosion of information collection, exchange and use in the life sciences industry. Your response will be anonymous and will provide important perspective to an influential research and development publication on this topic.

We strictly guard your privacy and absolutely no personally identifiable information will be shared under any circumstances. You will not receive any solicitations nor will you be added to any list for future contact. Any contact information solicited is for the sole purpose of sending gift cards to qualified respondents.

Click here to begin the survey. Thanks for taking time out of your day to help our research efforts. - Arsalan Arif, Publisher (twitter | email)

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.